Procter & Gamble Health · NSE: PGHL · BSE: 500126
Q3 FY23 results · Oct–Dec 2022
Procter & Gamble Health reported revenue from operations of ₹309.97 crore (up 11.5% from Q3 FY22) and net profit of ₹76.80 crore (up 71.3% from Q3 FY22) for Q3 FY23 (Oct–Dec 2022), on a standalone basis.
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 309.97 | 277.90 | +11.5% | 297.55 | +4.2% |
| Other income | 4.54 | 4.70 | −3.4% | 3.42 | +32.7% |
| Total income | 314.51 | 282.60 | +11.3% | 300.97 | +4.5% |
| Profit before tax | 104.94 | 59.83 | +75.4% | 86.60 | +21.2% |
| Net profit for the period | 76.80 | 44.84 | +71.3% | 63.66 | +20.6% |
| EPS, basic (₹) | 46.30 | 27.00 | +71.5% | 38.30 | not comparable |
| Net margin (%) | 24.8 | 16.1 | 21.4 |
Standalone
- Filed with BSE
- 06 Feb 2023, 14:46 IST
- Board meeting
- 05 Feb 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE